Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. reports company developments for a commercial-stage medical technology and healthcare business centered on neurohealth therapies. Its recurring updates cover the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation platform cleared by the U.S. Food and Drug Administration for adults with major depressive disorder, adjunctive use in obsessive-compulsive disorder, anxious depression symptoms in adults with MDD, and first-line adjunctive treatment of MDD in adolescent patients aged 15-21.
News about STIM also covers operating results, U.S. and international system revenue, clinic services added through the completed Greenbrook acquisition, SPRAVATO-related clinic activity, executive and board changes, inducement equity awards, shareholder engagement, and cost-structure actions.
Neuronetics (NASDAQ:STIM) announced a strategic collaboration with ANT Neuro to integrate ANT’s FDA-cleared visor2 neuronavigation with the NeuroStar TMS platform.
The partnership adds real-time spatial tracking and 3D visualization to support treatment visibility, consistency, and more personalized navigation, with broader rollout planned in the second half of 2026.
Neuronetics (NASDAQ: STIM) reported Q1 2026 revenue of $34.5 million, up 8% year‑over‑year, with U.S. clinic revenue of $21.5 million (up 15%). GAAP gross margin was 46.9%. Net loss narrowed to $10.8 million (‑$0.16/share). Cash on hand was $19.0 million.
Company reiterated 2026 guidance: total revenue $160–166M, gross margin 47–49%, operating expenses $100–105M, and expected negative operating cash flow of $13–17M.
Neuronetics (NASDAQ: STIM) announced inducement awards under Nasdaq Listing Rule 5635(c)(4) granted to six new non-executive employees on April 29, 2026. The grants comprise a total of 122,400 RSUs across the recipients, with vesting in thirds over three or four years and subject to continued service and the 2020 Inducement Incentive Plan.
The Compensation Committee approved the awards as material inducements to employment; vesting schedules vary by grant and are tied to service anniversaries.
Neuronetics (NASDAQ: STIM) will release first quarter 2026 financial and operating results before market open on Tuesday, May 5, 2026.
The company will host a conference call at 8:30 a.m. Eastern Time the same day, with a live listen-only webcast and telephone registration available for participants.
Neuronetics (NASDAQ: STIM) announced that Optum/United Healthcare/United Behavioral Health updated its Transcranial Magnetic Stimulation (TMS) clinical policy to allow psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer TMS where full practice authority (FPA) exists.
The change expands access to NeuroStar TMS across 26 states and Washington, D.C. and affects 34.8 million Optum/UHC/UBH commercial covered lives, increasing provider capacity for non-drug depression treatment.
Neuronetics (NASDAQ: STIM) responded to a public letter from Jorey Chernett at Pointillist Family Office dated April 6, 2026. The Company said the Board and management are committed to acting in all shareholders' best interests and regularly evaluate options to maximize shareholder value.
According to the Company, the Board reviewed the letter, values engagement with shareholders, and agrees the current valuation may not reflect the business strength; the Board is open to constructive engagement while executing strategic priorities to enhance long-term value.
Neuronetics (NASDAQ: STIM) announced that Steven E. Pfanstiel will resign as Executive Vice President, Chief Financial Officer, and Treasurer to pursue an opportunity outside the company and will remain through May 1, 2026 to support an orderly transition.
The company said the departure is not due to any dispute and that it has launched a search for a replacement. Neuronetics also reaffirmed its fiscal 2026 financial guidance previously provided on March 17, 2026.
Neuronetics (NASDAQ: STIM) largest independent shareholder, Jorey Chernett, delivered a letter on April 6, 2026 calling for an immediate, comprehensive review of strategic alternatives, including a potential sale of the Company's TMS business.
The letter cites a 14.12% ownership stake, argues that post-acquisition synergies have not materialized since December 2024, and claims applying comparable multiples implies 5–7x upside to current STIM equity value. Chernett urges the Board to engage advisors to evaluate all options and consider separating the clinic business as a standalone.
Neuronetics (NASDAQ: STIM) reported Q4 2025 revenue of $41.8M (up 86% YoY) and full year 2025 revenue of $149.2M (up 99% YoY), driven by the December 2024 Greenbrook acquisition and clinic revenue of $87.0M for 2025. Gross margin fell to 48.5% for 2025 and the company reported a $39.1M net loss. Cash totaled $34.1M at year-end. Guidance for 2026: revenue $160M–$166M, gross margin 47%–49%, operating expenses $100M–$105M.
Dan Reuvers will become CEO effective March 23, 2026; TRICARE West expanded TMS coverage for adolescents aged 15+.
Neuronetics (NASDAQ: STIM) appointed Dan Reuvers as President and Chief Executive Officer, effective March 23, 2026, and he will join the Board. He succeeds Keith Sullivan, who will step down March 23 and retire March 31, 2026. The company granted 1,500,000 RSUs vesting over three years as an inducement.
Reuvers brings 30+ years in medical devices, including scaling revenue at Tactile Medical from $187M to about $300M, and prior leadership at Integra LifeSciences. The RSU grant was approved under NASDAQ Listing Rule 5635(c)(4).